Literature DB >> 12652470

Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.

John E Levine1, Joseph P Uberti, Lois Ayash, Christopher Reynolds, James L m Ferrara, Samuel M Silver, Thomas Braun, Gregory Yanik, Raymond Hutchinson, Voravit Ratanatharathorn.   

Abstract

Reduced conditioning intensity has extended the option of allogeneic hematopoietic stem cell transplantation to patients who cannot tolerate fully myeloablative regimens. However, relapse and graft-versus-host disease (GVHD) continue to be major causes of morbidity and mortality. We prospectively tested whether a moderate reduction of the intensity of the preparative regimen would lead to significant reduction in regimen-related toxicity without compromising tumor control in a cohort of 44 patients ineligible for conventional hematopoietic stem cell transplantation. Patients were conditioned with fludarabine, busulfan, mycophenolate, and total lymphoid irradiation. Tacrolimus and methotrexate were given as prophylaxis for GVHD. Donors were 5 of 6 or 6 of 6 matched family members. The median age was 61 years. Eleven patients had comorbid conditions that precluded conventional myeloablative transplantation. Fatal regimen-related organ toxicity occurred in 3 patients. The cumulative incidence of grade 2 to 4 or grade 3 to 4 acute GVHD by day 100 was 38% (95% confidence interval [CI] = 25%, 55%) and 20% (95% CI = 10%, 39%), respectively, with a median time to onset of 66 days. For the entire cohort, 1-year overall survival, disease-free survival, and relapse rates were 54% (95% CI = 41%, 71%), 47% (95% CI = 35%, 65%), and 37% (95% CI = 19%, 51%), respectively. Outcomes differed based on stage of disease at time of transplantation, advanced (n = 19) versus nonadvanced (n = 25). Median survival times were 138 days and 685 days for subjects with advanced and nonadvanced disease, respectively (P =.005). After adjusting for age and comorbidity, disease stage continued to be significantly associated with overall survival (P =.005). In conclusion, a moderate reduction in conditioning dose intensity resulted in delayed onset of acute GVHD (compared with historical controls). A reduction in conditioning intensity is associated with poor survival for patients with advanced-stage disease, highlighting the importance of the conditioning regimen for tumor control. Copyright 2003 American Society for Blood and Marrow Transplantation

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12652470     DOI: 10.1053/bbmt.2003.50012

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  13 in total

Review 1.  Eicosanoid regulation of pulmonary innate immunity post-hematopoietic stem cell transplantation.

Authors:  Megan N Ballinger; Tracy R McMillan; Bethany B Moore
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007 Jan-Feb       Impact factor: 4.291

Review 2.  HDAC inhibition and graft versus host disease.

Authors:  Sung Choi; Pavan Reddy
Journal:  Mol Med       Date:  2011-01-08       Impact factor: 6.354

Review 3.  Implications of TNF-α in the pathogenesis and management of GVHD.

Authors:  John E Levine
Journal:  Int J Hematol       Date:  2011-03-08       Impact factor: 2.490

Review 4.  Emerging therapies in hematopoietic stem cell transplantation.

Authors:  Pavan Reddy; Marcos de Lima; John Koreth
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

5.  Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.

Authors:  Simrit Parmar; Gabriela Rondon; Marcos de Lima; Peter Thall; Ronald Bassett; Paolo Anderlini; Partow Kebriaei; Issa Khouri; Prasanth Ganesan; Richard Champlin; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2012-12-07       Impact factor: 5.742

6.  Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.

Authors:  Caron A Jacobson; Lixian Sun; Haesook T Kim; Sean M McDonough; Carol G Reynolds; Michael Schowalter; John Koreth; Corey S Cutler; Vincent T Ho; Edwin P Alyea; Philippe Armand; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-23       Impact factor: 5.742

Review 7.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

8.  Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation.

Authors:  Pavan Reddy
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

Review 9.  Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity?

Authors:  Inga Buchmann; Ralf G Meyer; Walter Mier; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-08       Impact factor: 9.236

Review 10.  The role of oral beclometasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease.

Authors:  Phuong L Doan; Nelson J Chao
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.